PNEUMO
Research type
Research Study
Full title
Pneumococcal pNeumonia Epidemiology, Urine serotyping, and Mental Outcomes. The PnEUmo Study in Europe.
IRAS ID
306031
Contact name
James D Chalmers
Contact email
Sponsor organisation
UMC Utrecht
Clinicaltrials.gov Identifier
N/A, N/A - not defined as a clinical trial
Duration of Study in the UK
2 years, 0 months, 30 days
Research summary
In order to inform vaccine development and public health policy, additional data are needed to understand the risk of infection from specific pneumococcal serotypes and the morbidity and mortality from these infections.
Objective: To describe the epidemiology, clinical characteristics and outcomes of adults hospitalized with pneumococcal community acquired pneumonia (CAP), including both bacteremic and non-bacteremic pneumococcal CAP, and other invasive pneumococcal diseases (IPD).
Design: Multicenter prospective observational cohort in France, Spain, Italy and as of September 2021 Germany and United Kingdom.
Outcomes:
1. Incidence of pneumococcal CAP and IPD including serotype prevalence based on urine antigen testing. Therefore a urine sample of every hospitalized patient with CAP or a lower respiratory tract infection acquired in the community has to be collected and sent to a reference laboratory.
2. Clinical characteristics of patients with pneumococcal CAP and IPD. Quality of life assessments up to 6 months post discharge will be done in a subset of participating hospitals.
3. Potentially: testing the study subjects for Respiratory Syncytial Virus (co-)infection (if locally available/standard of care)REC name
London - Harrow Research Ethics Committee
REC reference
22/LO/0190
Date of REC Opinion
29 Mar 2022
REC opinion
Further Information Favourable Opinion